
APGN
Healthcare · Biotechnology · $9.6M market cap
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Sep 30, 2023
EPS trend, 90 days to now · 0.0% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 2 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 14, 2023 | Time not confirmed | -0.19 | 0.00 | +100.0% |
| Aug 10, 2023 | After the close | -0.19 | -0.24 | -26.3% |
| May 16, 2023 | After the close | -0.19 | -0.25 | -31.6% |
| Feb 22, 2023 | After the close | -0.36 | -0.33 | +8.3% |
| Nov 15, 2022 | Before the open | -0.28 | -0.41 | -46.4% |
| Aug 18, 2022 | After the close | 0.00 | -0.46 | — |
| Apr 7, 2022 | After the close | — | -0.01 | — |
| Dec 9, 2021 | Time not confirmed | — | 0.01 | — |
| Aug 16, 2021 | Time not confirmed | — | -0.04 | — |
| Jun 7, 2021 | Time not confirmed | — | -0.02 | — |
| Jan 29, 2021 | Time not confirmed | — | 0.00 | — |
| Aug 14, 2020 | Time not confirmed | — | 0.00 | — |
Apexigen, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody therapeutics for oncology. It develops a pipeline of product candidates, including APX005M, a humanized agonist antibody that is in Phase II clinical development for the treatment of solid tumors, such as melanoma, esophageal and gastroesophageal junction, sarcoma, and ovarian cancers in combination with immunotherapy,…